Eli Lilly Corp. Stock

Eli Lilly shares could face pressure after Donald Trump reinforced his intention to impose tariffs on imported pharmaceuticals. The Republican president plans to implement duties of "25% or higher"

Eli Lilly has intensified its legal campaign against pharmacies producing unauthorized versions of its weight-loss medication tirzepatide. The pharmaceutical giant filed lawsuits against Strive

Eli Lilly's experimental drug Lepodisiran has delivered impressive results in Phase 2 clinical trials, reducing a genetic risk factor for heart disease by nearly 94 percent. The drug targets

Eli Lilly's stock has demonstrated remarkable resilience this year, gaining approximately 6% while Danish competitor Novo Nordisk faced significant losses. This divergence in performance reflects a

Eli Lilly faces a potential challenge to its dominant position in the lucrative GLP-1 market after Lexaria Bioscience Corp. reported breakthrough results with its oral DehydraTECH-tirzepatide

Eli Lilly's stock is facing pressure following a strategic partnership announcement between Swiss pharmaceutical giant Roche and Danish firm Zealand Pharma. The deal, valued at up to $5.3 billion

Eli Lilly has reported significant progress with its medication Ebglyss for moderate to severe atopic dermatitis. At the American Academy of Dermatology annual meeting in Orlando, the company

Pharmaceutical giant Eli Lilly and Company, now the world's most valuable pharma corporation with a market capitalization exceeding $855 billion, announced Wednesday it will invest an additional $27

Eli Lilly continues to demonstrate remarkable market performance, posting an impressive 32 percent revenue growth over the past twelve months. The pharmaceutical giant's robust financial health is

Eli Lilly and is strengthening its position in the lucrative weight management sector through a significant $2 billion acquisition of Versanis Bio. This strategic move centers on Bimagrumab, a